Literature DB >> 33665165

Genomic Assays in Node Positive Breast Cancer Patients: A Review.

Maroun Bou Zerdan1, Maryam Ibrahim2, Clara El Nakib1, Rayan Hajjar1, Hazem I Assi1.   

Abstract

In recent years, developments in breast cancer have allowed yet another realization of individualized medicine in the field of oncology. One of these advances is genomic assays, which are considered elements of standard clinical practice in the management of breast cancer. These assays are widely used today not only to measure recurrence risk in breast cancer patients at an early stage but also to tailor treatment as well and minimize avoidable treatment side effects. At present, genomic tests are applied extensively in node negative disease. In this article, we review the use of these tests in node positive disease, explore their ramifications on neoadjuvant chemotherapy decisions, highlight sufficiently powered recent studies emphasizing their use and review the most recent guidelines.
Copyright © 2021 Bou Zerdan, Ibrahim, Nakib, Hajjar and Assi.

Entities:  

Keywords:  Endopredict; MammaPrint; PAM50; breast cancer; breast cancer index; genomic grade index; immunohistochemistry; oncotype DX

Year:  2021        PMID： 33665165      PMCID： PMC7921691          DOI： 10.3389/fonc.2020.609100

Source DB:  PubMed          Journal:  Front Oncol        ISSN： 2234-943X            Impact factor:   6.244


  134 in total

1.  Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).

Authors:  Peter Beitsch; Pat Whitworth; Paul Baron; Michael C Rotkis; Angela M Mislowsky; Paul D Richards; Mary K Murray; James V Pellicane; Carrie L Dul; Charles H Nash; Lisette Stork-Sloots; Femke de Snoo; Sarah Untch; Laura A Lee
Journal:  Ann Surg Oncol       Date:  2017-04-26       Impact factor: 5.344

2.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

3.  Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

Authors:  Francisco J Esteva; Aysegul A Sahin; Massimo Cristofanilli; Kevin Coombes; Sang-Joon Lee; Joffre Baker; Maureen Cronin; Michael Walker; Drew Watson; Steven Shak; Gabriel N Hortobagyi
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

4.  Positive association between cognitive ability and cortical thickness in a representative US sample of healthy 6 to 18 year-olds.

Authors:  Karama S; Ad-Dab'bagh Y; Haier Rj; Deary Ij; Lyttelton Oc; Lepage C; Evans Ac
Journal:  Intelligence       Date:  2009-03

5.  Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).

Authors:  Bernhard C Pestalozzi; Christoph Tausch; Konstantin J Dedes; Christoph Rochlitz; Stefan Zimmermann; Roger von Moos; Ralph Winterhalder; Thomas Ruhstaller; Andreas Mueller; Katharina Buser; Markus Borner; Urban Novak; Catrina Uhlmann Nussbaum; Bettina Seifert; Martin Bigler; Vincent Bize; Simona Berardi Vilei; Christoph Rageth; Stefan Aebi
Journal:  BMC Cancer       Date:  2017-04-13       Impact factor: 4.430

6.  Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.

Authors:  Pat Whitworth; Peter Beitsch; Angela Mislowsky; James V Pellicane; Charles Nash; Mary Murray; Laura A Lee; Carrie L Dul; Michael Rotkis; Paul Baron; Lisette Stork-Sloots; Femke A de Snoo; Jennifer Beatty
Journal:  Ann Surg Oncol       Date:  2016-10-21       Impact factor: 5.344

7.  Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients.

Authors:  Hazem I Assi; Ibrahim A Alameh; Jessica Khoury; Nour Abdul Halim; Fadi El Karak; Fadi Farhat; Juliett Berro; Eman Sbaity; Maya Charafeddine; Arafat Tfayli; Ziad Salem; Nagi El Saghir
Journal:  J Oncol       Date:  2020-11-28       Impact factor: 4.375

8.  Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Ivana Sestak; Richard Buus; Jack Cuzick; Peter Dubsky; Ralf Kronenwett; Carsten Denkert; Sean Ferree; Dennis Sgroi; Catherine Schnabel; Frederick L Baehner; Elizabeth Mallon; Mitch Dowsett
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

9.  Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.

Authors:  Lorenza Mittempergher; Leonie Jmj Delahaye; Anke T Witteveen; Mireille Hj Snel; Sammy Mee; Bob Y Chan; Christa Dreezen; Naomi Besseling; Ernest Jt Luiten
Journal:  Transl Oncol       Date:  2020-03-21       Impact factor: 4.243

10.  Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.

Authors:  J M S Bartlett; D C Sgroi; K Treuner; Y Zhang; I Ahmed; T Piper; R Salunga; E F Brachtel; S J Pirrie; C A Schnabel; D W Rea
Journal:  Ann Oncol       Date:  2019-11-01       Impact factor: 32.976
View more
  3 in total

Review 1.  Breast cancer in the era of precision medicine.

Authors:  Negar Sarhangi; Shahrzad Hajjari; Seyede Fatemeh Heydari; Maryam Ganjizadeh; Fatemeh Rouhollah; Mandana Hasanzad
Journal:  Mol Biol Rep       Date:  2022-06-22       Impact factor: 2.742

Review 2.  Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?

Authors:  Liqin Yao; Gang Jia; Lingeng Lu; Wenxue Ma
Journal:  Curr Oncol       Date:  2022-07-12       Impact factor: 3.109

3.  Characterization of Gene Expression Signatures for the Identification of Cellular Heterogeneity in the Developing Mammary Gland.

Authors:  Samantha Henry; Marygrace C Trousdell; Samantha L Cyrill; Yixin Zhao; Mary J Feigman; Julia M Bouhuis; Dominik A Aylard; Adam Siepel; Camila O Dos Santos
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-05-14       Impact factor: 2.673
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.